Omnix Medical Ltd, based in Israel, has raised $25 million from a Series C funding round to accelerate development of a pipeline of antimicrobials directed against multidrug-resistant infections. Announced on 15 October, the financing was co-led by Harel Insurance & Finance Group, one of Israel’s largest financial institutions, and the European Innovation Council Fund, a venture initiative of the European Commission under the Horizon Europe research programme.
Tubulis GmbH, a German company with a portfolio of antibody-drug conjugates, has raised €308 million in a Series C financing round in what is being described as the largest C round for a European biotechnology company and the biggest financing globally for a private ADC developer. Announced on 15 October, the round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital.
Bristol Myers Squibb Co has stepped up its commitment to cell therapies with plans to spend $1.5 billion to acquire a Cambridge, Massachusetts biotech which is developing a medicine to reprogramme the immune system and treat autoimmune diseases. Orbital’s lead product, OTX-201, is an in vivo chimeric antigen receptor (CAR) T cell therapy that is being developed using ribonucleic acid (RNA) technology. The preclinical product consists of a circular RNA that encodes a CAR which targets cells expressing CD19, a B cell specific antigen.
AstraZeneca Plc has become the second global pharmaceutical company to sign an agreement with the Trump Administration to lower the prices of its medicines sold in the US. In parallel it will increase its manufacturing presence in the country and upgrade its share listing. Pfizer Inc signed a similar agreement with the government on 30 September. The deals are applications of the World Trade Organization’s most-favoured nation principle (MFN) under which favourable terms of trade, like lower tariffs, extended to one country are granted to other WHO members as well.
Genmab A/S is to take over the Dutch company Merus NV for $8 billion in one of the largest European biotech transactions to date, giving it new tools for treating a host of cancers. Merus has a portfolio of bispecific and trispecific antibodies which are recombinant molecules that bind to one or more targets at the same time. The company has one marketed product, Bizengri (zenocutuzumab), which has been approved for non-small cell lung and pancreatic cancers, and a second, petosemtamab, which is in development for head and neck and colorectal cancers.
Restructuring across the biotech industry has resulted in decisions by three companies to end programmes in cell therapy after investing heavily in the sector for several years. On 30 September, Heartseed Inc of Japan announced that partner Novo Nordisk A/S, was ending a collaboration to create a stem cell-based therapy for heart failure. In separate announcements on 1 October, Takeda Pharmaceutical Co Ltd of Japan and Galapagos NV of the Netherlands announced plans to discontinue or divest cell therapy progammes in cancer.
An Italian university, hospital, and biotech and diagnostic companies, have joined forces to develop new treatments for lung cancer patients targeting the human epidermal growth factor receptor 3 (HER3). The collaboration is expected to identify HER3-positive circulating tumour cells with the goal of developing targeted therapies for the disease. It includes the Sant’Andrea Hospital in Rome, the Department of Clinical and Molecular Medicine at Sapienza University, also in Rome, the biotech company Takis Srl, and the diagnostics company Tethis SpA.
GSK Plc has appointed Luke Miels as chief executive officer designate, as well as a member of the company’s board of directors, from 1 January 2026. Emma Walmsley, the current CEO who has led the company since 2017, will step down from her position. However she will remain with the business until her notice period ends on 30 September 2026.
A gene therapy intended as a one-time treatment for Huntington’s disease significantly slowed progression of the disorder in a pivotal Phase 1/2 trial, paving the way for a regulatory submission in the first quarter of 2026. The developer, uniQure NV, showed that it is possible to safely impact the disease by targeting both the disease-causing huntingtin protein and the normal protein using a vector-based gene therapy and a gene encoding a microRNA (miRNA).
Pfizer Inc is to pay $4.9 billion to acquire a three-year old company, Metsera Inc, which is developing drugs for weight management giving it a selection of candidate products that can be delivered orally and by injection and which include both amylin and incretin mimetics. The amylin-based treatments restore sensitivity to leptin, a satiety hormone that enables people to feel naturally full after eating. The incretins, which include the glucagon-like peptide-1 (GLP-1) drugs, mimic hormones in the gut that help regulate blood sugar and appetite.